Crossmark

Neuroinflammation and metabolic dysregulation as predictors of cognitive impairment, depression, and quality of life in type 2 diabetes mellitus patients on SGLT2 inhibitors and sulfonylureas

Crossref DOI link: https://doi.org/10.1007/s10787-025-01824-9

Published Online: 2025-06-27

Published Print: 2025-08

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Majid, Haya

Islam, Sajad Ul

Kohli, Sunil

Nidhi,
License Information

Text and Data Mining valid from 2025-06-27

Version of Record valid from 2025-06-27
More Information

Article History

Received: 9 May 2025

Accepted: 6 June 2025

First Online: 27 June 2025

Declarations

:

: The authors have no competing interests to declare that are relevant to the content of this article.

: The protocol and the informed consent form were approved by the Jamia Hamdard Institutional Ethics Committee (JH/IEC/03/2024) before the initiation of the study. It was conducted by the ethical guidelines for biomedical research involving human participation set forth by the Indian Council for Medical Research (ICMR) in 2017, as well as the guidelines on good clinical practice established by the Central Drugs Standard Control Organization (CDSCO) and the principles outlined in the Declaration of Helsinki.

: Informed consent was obtained from all individual participants included in the study.

Document is current

Any future updates will be listed below